Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL523117 | 0.94 | LPAR1 (0.37) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL3466840 | 0.80 | KDM4E (0.45) | L3MBTL1LMNAHRH1KDM4EALDH1A1 | |
| SCHEMBL19384155 | 0.78 | HTR1D (0.56) | L3MBTL1LMNA | |
| SCHEMBL524022 | 0.74 | LPAR1 (0.46) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL5933377 | 0.72 | TDP1 (0.66) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL16524239 | 0.71 | ALDH1A1 (0.41) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL19384146 | 0.68 | HTR1D (0.51) | MEN1KMT2AL3MBTL1LMNAKDM4E | |
| SCHEMBL19405089 | 0.68 | HTR1D (0.53) | MEN1KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL4731326 | 0.67 | TDP1 (0.58) | MEN1KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL451750 | 0.67 | MAPT (0.46) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | MEN1 4725/4885KMT2A 503/4885NPC1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.